This company is no longer active
Magenta Therapeutics Past Earnings Performance
Past criteria checks 0/6
Magenta Therapeutics's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 22.7% annually.
Key information
-6.3%
Earnings growth rate
41.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -92.1% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01Revenue & Expenses BreakdownBeta
How Magenta Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 0 | -69 | 23 | 35 |
31 Mar 23 | 0 | -83 | 25 | 47 |
31 Dec 22 | 0 | -76 | 26 | 55 |
30 Sep 22 | 0 | -76 | 27 | 52 |
30 Jun 22 | 0 | -77 | 28 | 52 |
31 Mar 22 | 0 | -77 | 28 | 52 |
31 Dec 21 | 0 | -71 | 28 | 47 |
30 Sep 21 | 0 | -70 | 28 | 46 |
30 Jun 21 | 0 | -70 | 27 | 47 |
31 Mar 21 | 0 | -72 | 28 | 48 |
31 Dec 20 | 0 | -75 | 28 | 51 |
30 Sep 20 | 0 | -80 | 27 | 57 |
30 Jun 20 | 0 | -83 | 27 | 62 |
31 Mar 20 | 0 | -82 | 25 | 63 |
31 Dec 19 | 0 | -77 | 24 | 59 |
30 Sep 19 | 0 | -70 | 23 | 53 |
30 Jun 19 | 0 | -65 | 23 | 48 |
31 Mar 19 | 0 | -61 | 21 | 44 |
31 Dec 18 | 0 | -58 | 19 | 41 |
30 Sep 18 | 0 | -49 | 16 | 35 |
30 Jun 18 | 0 | -40 | 12 | 28 |
31 Mar 18 | 0 | -42 | 10 | 32 |
31 Dec 17 | 0 | -36 | 8 | 28 |
Quality Earnings: MGTA is currently unprofitable.
Growing Profit Margin: MGTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MGTA is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare MGTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Return on Equity
High ROE: MGTA has a negative Return on Equity (-92.08%), as it is currently unprofitable.